Agricultural inputs: IAS 41 boundary

While rare across pure manufacturing processors, integrated dairy, poultry and agri-food groups that own the biological assets feeding their plants face genuine fair-value volatility flowing through operating profit each period, and confusing purchased inputs with owned biological assets either introduces spurious earnings volatility or masks the fair value swings regulators and investors expect for integrated agricultural operations.

Does the manufacturer legally own and manage the biological assets (herd, flock, crops) feeding its plant, or does it only purchase already-harvested inputs from third-party farmers? If owned, are the biological assets measured at fair value less costs to sell each reporting date, with changes through profit or loss, rather than being treated as inventory at cost? Are reliable fair value inputs (active market prices or a defensible discounted cash flow model) actually available?

1. Determine whether the manufacturer legally owns and manages biological assets (e.g. a dairy herd, poultry flock, or crops on owned/controlled farmland) versus simply purchasing already-harvested inputs (milk, grain, livestock) from third-party farmers.
2. Purchased raw materials (milk, grain, live animals bought for immediate slaughter/processing) are recognized directly as inventory under IAS 2 at cost - IAS 41 does not apply to purchased inputs.
3. For owned biological assets, recognize and measure them at fair value less costs to sell from initial recognition through to the point of harvest, unless fair value cannot be measured reliably (rare, and only permitted at initial recognition for certain assets).
4. At the point of harvest, the produce is measured at fair value less costs to sell at that date, and this fair value becomes the deemed cost/opening carrying amount of inventory going forward.
5. From the point of harvest onward, apply IAS 2 to the harvested produce (now inventory) - measure at the lower of that deemed cost and net realizable value.
6. Reassess at each reporting date the fair value of any biological assets still held (not yet harvested), recognizing the change in profit or loss.
7. Confirm reliable fair value inputs are available; if measuring fair value is genuinely not possible (extremely rare) cost less accumulated depreciation/impairment may be used only at initial recognition.

Owned biological assets are measured at fair value less costs to sell at each reporting date from initial recognition until harvest, with changes recognized in profit or loss, reflecting an active-market price or a present value of expected net cash flows using a market-determined discount rate. Agricultural produce is measured at fair value less costs to sell at the point of harvest, which then becomes its cost for IAS 2 purposes going forward. Purchased inputs never enter the IAS 41 fair value model. Remeasurement of biological assets is triggered at every reporting date while remeasurement of harvested produce as inventory follows the normal IAS 2 net realizable value review cycle.

Disclose a reconciliation of the carrying amount of biological assets from opening to closing balance, showing fair value gains/losses, purchases, sales, and harvest transfers to inventory; disclose valuation methods and significant assumptions used to determine fair value; disclose the fair value less costs to sell of agricultural produce recognized at the point of harvest; disclose quantities and physical description of biological assets held; disclose government grants related to biological assets separately; distinguish purchased inventory (IAS 2) from biological assets (IAS 41) clearly in the notes.

• Applying IAS 41 fair value accounting to purchased inputs that should simply be inventory at cost under IAS 2
• carrying owned herds or crops at historical cost instead of fair value less costs to sell
• failing to re-measure harvested produce at fair value less costs to sell at the exact point of harvest
• omitting the fair value gain/loss on biological assets from operating profit disclosure
• not distinguishing consumable biological assets from bearer biological assets in disclosures.